BioSpace News Archive

Regeneron Pharmaceuticals, Inc. will webcast management participation. The sessions may be accessed from the “Investors & Media” page of Regeneron’s website.

Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the fourth quarter of fiscal year 2021.

Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted to 23 new employees inducement stock options to purchase an aggregate of 39,400 shares of its common stock and 18,760 inducement restricted stock units.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock.

Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, announced it has commenced an underwritten public offering of shares of its common stock.

In addition to technical and business advisory services provided by NRC IRAP, the funding will be utilized by BDS to perform validation and verification studies including the completion of internal standards development with a clear objective of accelerating the commercialization of BioMark’s liquid biopsy platform for early lung cancer detection.

The U.S. Food and Drug Administration today authorized marketing of EaseVRx, a prescription-use immersive virtual reality (VR) system that uses cognitive behavioral therapy and other behavioral methods to help with pain reduction in patients 18 years of age and older with diagnosed chronic lower back pain.

Padagis today announced the first-to-market launch of an AB-rated generic version of Zomig® Nasal Spray. Zomig® Nasal Spray is distributed in a unique unit dose presentation and is indicated for t

Scipher Medicine, a precision immunology company matching patients with their most effective medication therapies, today announced the appointment of Sam Asgarian, M.D., MBA, as chief medical officer.

Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the hiring of Mr. David Barthel as the Chief Executive Officer for Marizyme.